EP0827514A1 - Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions - Google Patents

Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions

Info

Publication number
EP0827514A1
EP0827514A1 EP96916030A EP96916030A EP0827514A1 EP 0827514 A1 EP0827514 A1 EP 0827514A1 EP 96916030 A EP96916030 A EP 96916030A EP 96916030 A EP96916030 A EP 96916030A EP 0827514 A1 EP0827514 A1 EP 0827514A1
Authority
EP
European Patent Office
Prior art keywords
hyaluronic acid
hemiester
succinic
heavy metal
succinic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP96916030A
Other languages
German (de)
French (fr)
Other versions
EP0827514B1 (en
Inventor
Riaz Khan
A. Paul Konowicz
Antonella Flaibani
Valentina Gombac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anika Therapeutics SRL
Original Assignee
Fidia Advanced Biopolymers SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Advanced Biopolymers SRL filed Critical Fidia Advanced Biopolymers SRL
Publication of EP0827514A1 publication Critical patent/EP0827514A1/en
Application granted granted Critical
Publication of EP0827514B1 publication Critical patent/EP0827514B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to succinic acid hemiesters with hyaluronic acid or with hyaluronic acid partial or total esters, and heavy metal salts of said succinic hemiesters with hyaluronic acid or hyaluronic acid total or partial esters , a process for their preparation and pharmaceutical compositions containing these salts as active ingredients.
  • Hyaluronic acid is a polysaccharide whose chain is constituted by alternating units of 1,4-fS-D-glucuronic acid and l,3- ⁇ -N-acetyl-D- glucos mine.
  • Hyaluronic acid is a fundamental component of the connective tissue of animals, being present, for example, in the skin and cartilage. It is also found in high concentrations in the umbilical cord, in the synovial fluid and vitreous humor of the eye.
  • the preferred source of hyaluronic acid is by extraction from cockscombs, even though the production of hyaluronic acid from Streptococcus cultures is becoming increasingly widespread (T. J. Lieselang. Survey of Ophthalmology 34,268-293. 1990).
  • hyaluronic acid is a fundamental component of the connective tissue, it is biocompatible, bioadsorbable and not immunogenic. It therefore plays a key role in many biological functions, such as tissue hydration, the organization of proteoglycans in the cartilage. tissue repair, embryonic development and lubrication and protection of joint cartilage. This polysaccharide is commonly used in the treatment of some joint diseases, such as rheumatoid arthritis. It is also used in what is known as microviscosurgery, and in particular, in surgery to the eye. In this application, the biocompatibility and Theological characteristics of concentrated solutions of high-molecular-weight hyaluronic acid are exploited.
  • hyaluronic acid is degraded by superoxide radicals (Greenwald R. A. et al., Inflammation, 10, 15-30, 1986) .
  • This degradation determines a notable reduction in the rheological and viscoelastic characteristics of the synovial fluid, markedly reducing the lubricant and protective effect which hyaluronic acid has on the cartilage.
  • the superoxide dismutase enzyme constitutes the main defense against damage caused by the superoxide radical which is produced in the course of inflammatory processes. Copper and zinc are components of the superoxide dismutase enzyme, the function of which seems to be to protect cells from the toxic effects of endogenous superoxide radicals.
  • Gold salts are also used as drugs to treat arthritis, together with known antiinflammatory products of a steroid and non-steroid type (US 4,746.504).
  • Many silver salts such as silver fluoride, silver iodide, silver lactate, have been used as antibacterial agents for topical use. Their antimicrobial activity is due to the action of the Ag+ ions.
  • Heavy metal salts of hyaluronic acid are therefore already known to the state of the art, such as silver, gold, cerium and tungsten. The reaction between a sodium hyaluronate aqueous solution and a silver nitrate solution gives the silver salt of hyaluronic acid.
  • compositions containing all these compounds are used to advantage for the treatment of burns, wounds and some ophthalmic infections such as gonococcus-induced conjunctivitis (A. Nimrod and B. Greenman, US Patent No. 4,746,504, May 24, 1988) .
  • the present invention concerns a succinic hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester and its inorganic salt with a heavy metal.
  • succinic acid hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester is characterized by having the following repeating unit (I):
  • R j _ , R2 and R equal or different from each other are H or C0- (CH2)2- C00Y ' wherein Y is a negative charge or H, R is OH, 0 " or an alcoholic residue.
  • the hyaluronic acid esters contemplated for preparing the succinic acid hemiester are the total or partial ester with alcohol of the aliphatic or cycloaliphatic series, which do not themselves possess a notable pharmacological action disclosed in USP 4 ,851.521, which we incorporate herewith by reference.
  • the heavy metal salt of the succinic acid hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester are in particular characterized by having the following repeating unit (II):
  • the heavy metal salts according to the present invention are characterized by having a far greater negative charge density than the corresponding heavy metal salt of the starting hyaluronate . Indeed, the new substituting group, i.e. succinic acid.
  • a further subject of the present invention relates to the process for preparing said succinic acid hemiester with hyaluronic acid or with a hyaluronic acid partial ester and the corresponding heavy metal salt.
  • the process according to the present invention contemplates the following steps: b') treating the hyaluronic acid ester dissolved or suspended in a mixture of water and an aprotic solvent with succinic anhydride in the presence of an organic base, as the catalyst, thereby obtaining the succinic acid hemiester having the repeating units (I) wherein R is a residue of an alcohol, and optionally recovering the obtained product by freeze-drying, c' ) treating the solution directly coming from the preceding step or an aqueous solution of the recovered solid product coming from the preceding step with an aqueous solution of an inorganic salt of the heavy metal, and recovering the product by filtration and vacuum drying.
  • the heavy metal salts of succinic acid hemiester with a hyaluronic acid or with a partial or total hyaluronic acid ester according to the present invention can be used to advantage as antimicrobial, antibacterial and disinfectant agents, for the treatment of wounds, burns and ophthalmia, or they can be incorporated in suitable pharmaceutical forms, optionally in association with one or more other pharmacologically active substances, having a similar therapeutic activity.
  • disinfectant agents not only for the preparation of drugs, but also as active ingredients for the preparation of the so-called health care products, such as cosmetic creams and ointments, shave and after shave lotions and hair lotions etc. or biomaterials such as membranes non-woven tissues. gauzes , etc.
  • the heavy metal salts of succinyl monoesters of hyaluronic acid can be also advantageously used as antiinflammatory agents in the treatment of arthritis and inflammations affecting the joints optionally in association with other pharmaceutically active principles having a similar therapeutical activity.
  • the term "heavy metal” encompasses any pharmaceutically active metal in the 4, 5 or 6 period of the periodic table.
  • the preferred heavy metal salts according to the present invention are those whose cation is: zinc, silver, copper, gold, cerium and tungsten salts of succinic derivatives of hyaluronic acid. It has in fact been found that compared with the corresponding salts with hyaluronic acid or with hyaluronic acid partial esters these salts offer an advantage over the already-known products containing heavy metal salts, because the salts according to the present invention can bind a high number of heavy metal cations. Indeed, while hyaluronic acid can bind only one counter-ion per repeating unit, the salts according to the present invention bind at least twice as many counter-ions per repeating unit.
  • Hyaluronic acid or hyaluronic acid esters of any molecular weight can be used to prepare succinyl derivatives thereof.
  • samples of hyaluronic acid with a molecular weight of between 30,000 and 760,000 Daltons were used, but this range is not critical for the purpose of the present invention.
  • step (a) the hyaluronic acid is preferably converted to the corresponding pyridinium salt.
  • this conversion encompasses a previous dissolution of the hyaluronate sodium salt in a mixture of water and dimethylformamide, a treatment with a cationic exchange resin for obtaining the corresponding free hyaluronic acid. After removal of the resin the solution is neutralized with pyridine and the pyridinium salt is thus obtained.
  • step (b ) or (b 1 ) of both processes the amount of succinic anhydride is not critical , although it is preferable to add high excess with respect to hyaluronic acid. In fact the best results are obtained when the molar ratio of succinic anhydride /free OH groups present in the repeating unit ( III)
  • the temperature is not critical, the best results are obtained if step (b) or (b' ) of both processes is carried out at 70 ⁇ C .
  • the preferred organic base used as catalyst in step (b ) or (b ' ) of both processes is selected from the group consisting of 4-dimethylaminopyridine , pyridine, or mixtures thereof .
  • the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of silver nitrate to form the silver salt of succinate hemiester with hyaluronic acid or hyaluronic acid ester.
  • the Ag salt according to the present invention precipitates from the solution and is recovered by filtration or centrifugation. The precipitate is then washed with ethanol and vacuum dried at 4 ⁇ °C.
  • the silver compounds of the succinyl derivatives are prepared in the complete dark. All the operations to prepare the silver nitrate solutions, and to prepare the succinyl silver hyaluronate were performed in the dark and the resulting products were stored away from sources of light.
  • the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of CuCl2 to form the Cu salt of succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.
  • step (c) or (c') of both processes the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of ZnCl2 to form the Zn salts of the succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.
  • step (c) or (c 1 ) of both processes the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of HAuCl ⁇ to form the Au salts of the succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.
  • compositions according to the present invention to be used for the treatment of burns, wounds and ophthalmia preferably contain the Ag salt according to the present invention and are moreover in the form of ointments, creams gels.
  • compositions to be used for the treatment of osteoarticular diseases preferably contain Au, Zn, Cu salts or mixtures thereof.
  • the solution was then neutralized with an excess of pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py) .
  • the viscous solution was then carefully evaporated in a vacuum to remove the water present, taking care not to allow the total volume of solution to drop below about 100 ml.
  • N.M.R. Analysis shows a degree of succinylation on carbon 6 of the N- acetylglucosamine (N-6) of 0.2 (mol of succinic acid/mol of repeating unit of the polymer) .
  • Example 2 A solution of sodium hyaluronate (HA-Na, 1 g, MW 30,000) in distilled water (35 ml) and N,N-dimethylformamide (DMF, 100 ml) was stirred in the presence of ion exchange resin (3 g, IR 120 H+) for 10 minutes and then the resin was removed by filtration after further dilution with DMF (100 ml).
  • ion exchange resin 3 g, IR 120 H+
  • the solution was then neutralized with an excess of pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py) .
  • the viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 100 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml).
  • the solution was then treated with succinic anhydride (3 g) and pyridine (10 ml) while being stirred at 70°C for 24 hours.
  • N.M.R. analysis gives a degree of succinylation on carbon 6 of the Nacetylglucosamine (N-6) of about 0.45 (mol of succinic acid/mol of repeating unit.
  • Example 3 A solution of sodium hyaluronate (HA-Na, 0.5 g. MW 160,000) in distilled water (35 ml) and N,N-dimethylformamide (DMF 100 ml) was stirred in the presence of ion exchange resin (3 G, IR 120 H+) for 10 minutes and then the resin was removed by filtration after further dilution with DMF (75 ml).
  • ion exchange resin 3 G, IR 120 H+
  • the solution was then neutralized with an excess of pyridine (6 ml) to give the pyridine salt of hyaluronic acid (HA-Py) .
  • the viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 50 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (10 ml).
  • the solution was then treated with succinic anhydride (2 g) , 4-dimethylaminopyridine (10 mg) and pyridine (10 ml), while stirring at 70°C for 48 hours. Further quantities of succinic anhydride were added (1 g) and pyridine (2.5 ml) and the mixture was stirred for another 24 hours.
  • Example 5 A solution of sodium hyaluronate (HA-Na, 1 g, MW 40,000) in distilled water (60 ml) and N,N-dimethylformamide (DMF 60 ml) was stirred in the presence of ion exchange resin (1 g, IR 120 H+) for 10 minutes, after which the resin was removed by filtration after further dilution with DMF (50 ml).
  • HA-Na sodium hyaluronate
  • DMF 60 ml N,N-dimethylformamide
  • the solution was then neutralized with an excess of pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py) .
  • the viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below 0 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml).
  • the solution was then treated with succinic anhydride (3 g) and pyridine (10 ml) at 70°C while stirring for 18 hours. Further quantities of succinic anhydride (2.5 g) and 4dimethylaminopyridine (200 mg) were added and the mixture was stirred for another 24 hours.
  • a solution of sodium hyaluronate (HA-Na, 0.5 g. MW 760,000) in distilled water (60 ml) and N,N-dimethylformamide (DMG 60 ml) was stirred in the presence of ion exchange resin (1 g, IR 120 H+) for 10 minutes, after which the resin was removed by filtration after further dilution with DMF (50 ml).
  • the solution was then neutralized with an excess of pyridine (6 ml) to give the pyridine salt of hyaluronic acid (HA-Py) .
  • the viscous solution was then carefully evaporated to remove the water present, without allowing the total volume of solution to drop below about 50 ml.
  • Example 8 70 mg of hyaluronic acid succinylate, prepared as described in Example 3 were dissolved in 14 ml of distilled water.
  • the polymer solution which was highly viscous, was supplemented with 14 ml of a solution of AgNO IN.
  • Atomic absorption analysis showed the silver content to be 21% in weight, equal to 11% of the theoretical stoichiometric value.
  • Example 9 100 mg of hyaluronic acid succinylate, prepared as described in Example 4, were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of AgNO 2N. A white precipitate formed immediately and was kept in suspension while being constantly stirred for two hours. It was then recovered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven set at 4 ⁇ ⁇ C. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 28.8% in weight, equal to 70.5% of the theoretical stoichiometric value.
  • Example 10 100 mg of hyaluronic acid succinylate, prepared as described in Example 4, were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of AgNO 2N. A white precipitate formed immediately and was kept in suspension
  • Example 11 100 mg of hyaluronic acid succinylate, prepared as described in Example 6, were dissolved in 10 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 10 ml of a solution of AgNO IN. A brownish precipitate was immediately formed, which was kept in suspension while being constantly stirred for two hours, after which it was recovered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven set at 40 C C. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 21% in weight, equal to 11% of the theoretical stoichiometric value.
  • Example 13 100 mg of hyaluronic acid succinylate, prepared as described in Example 1 were dissolved in 10 ml of distilled water. The polymer solution was then supplemented with 10 ml of a solution of ZnCl 2 0.2 N. The solution was stirred constantly for 2 hours, after which 3 volumes of ethanol were added to precipitate the soluble zinc salt. The precipitate was recovered by centrifugation at 3.000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 4 ⁇ °C. Atomic absorption analysis showed a zinc content of 10 , equal to 101% of the theoretical stoichiometric value.
  • Example 13 100 mg of hyaluronic acid succinylate, prepared as described in Example 1 were dissolved in 10 ml of distilled water. The polymer solution was then supplemented with 10 ml of a solution of ZnCl 2 0.2 N. The solution was stirred constantly for 2 hours, after which 3 volumes of ethanol were added to precipitate the
  • Example of the preparation of gold salt of hyaluronic acid succinylate 100 mg of hyaluronic acid succinylate prepared as described in Example 3 were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was then supplemented with 20 ml of a solution of HAuCLi j 0.5N. After addition of gold salt, a precipitate was formed which was recovered by centrifugation at 3.000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven at 4 ⁇ c C. The gold content in the sample proved to be 13% in weight, equal to 44% of the theoretical stoichiometric value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Hyaluronic acid or hyaluronic acid ester derivatives, wherein one or more hydroxy functions of its 1,4-β-D-glucuronic acid and 1,3-β-N-acetyl-D-glucosamine alternating repeating units are esterified with a carboxyl group of succinic acid to form the succinic hemiester of hyaluronic acid or hyaluronic acid esters. These derivatives are used to prepare the corresponding heavy metal salts of succinic hemiesters of hyaluronic acid or with hyaluronic acid partial or total esters. These salts are used as active ingredients in the preparation of pharmaceutical compositions to be used as antibacterial and disinfectant agents for the treatment of wounds, burns and ophthalmia or as anti-inflammatory agents in particular for the preparation of pharmaceutical compositions for the treatment of osteoarticular disorders.

Description

HEAVY METAL SALTS OF SUCCINIC ACID HEMIESTERS WITH HYALURONIC ACID, OR HYALURONIC ACID ESTERS, A PROCESS FOR THEIR PREPARATION, AND RELATIVE PHARMACEUTICAL COMPOSITIONS FIELD OF THE INVENTION The present invention relates to succinic acid hemiesters with hyaluronic acid or with hyaluronic acid partial or total esters, and heavy metal salts of said succinic hemiesters with hyaluronic acid or hyaluronic acid total or partial esters , a process for their preparation and pharmaceutical compositions containing these salts as active ingredients.
BACKGROUND OF THE INVENTION
Hyaluronic acid is a polysaccharide whose chain is constituted by alternating units of 1,4-fS-D-glucuronic acid and l,3-β-N-acetyl-D- glucos mine. Hyaluronic acid is a fundamental component of the connective tissue of animals, being present, for example, in the skin and cartilage. It is also found in high concentrations in the umbilical cord, in the synovial fluid and vitreous humor of the eye. Currently, the preferred source of hyaluronic acid is by extraction from cockscombs, even though the production of hyaluronic acid from Streptococcus cultures is becoming increasingly widespread (T. J. Lieselang. Survey of Ophthalmology 34,268-293. 1990). As hyaluronic acid is a fundamental component of the connective tissue, it is biocompatible, bioadsorbable and not immunogenic. It therefore plays a key role in many biological functions, such as tissue hydration, the organization of proteoglycans in the cartilage. tissue repair, embryonic development and lubrication and protection of joint cartilage. This polysaccharide is commonly used in the treatment of some joint diseases, such as rheumatoid arthritis. It is also used in what is known as microviscosurgery, and in particular, in surgery to the eye. In this application, the biocompatibility and Theological characteristics of concentrated solutions of high-molecular-weight hyaluronic acid are exploited.
In cases of inflammation of the joints, hyaluronic acid is degraded by superoxide radicals (Greenwald R. A. et al., Inflammation, 10, 15-30, 1986) . This degradation determines a notable reduction in the rheological and viscoelastic characteristics of the synovial fluid, markedly reducing the lubricant and protective effect which hyaluronic acid has on the cartilage. It has been hypothesized that the superoxide dismutase enzyme constitutes the main defense against damage caused by the superoxide radical which is produced in the course of inflammatory processes. Copper and zinc are components of the superoxide dismutase enzyme, the function of which seems to be to protect cells from the toxic effects of endogenous superoxide radicals. Rheumatoid arthritis has been associated with zinc deficiencies and an antiinflammatory activity has been hypothesized for zinc itself (A. Frigo et al., "Copper and Zinc in Inflammation", Inflammation and drug therapy series, Vol. IV, Kluwer Academic Publishers, pp. 133-1^2, 1989). Treatment with zinc sulfate has proved to be efficacious in controlling joint disorders caused by arthritis in patients affected by psoriasis. In the same way, alterations in copper concentrations have been observed in patients affected by inflammatory diseases in the joints (C. W. Denko, "Copper and Zinc in Inflammation, Inflammation and drug therapy series. Vol. IV, Kluwer Academic Publishers, pp. 1-5, 1989). Copper-based compounds have been used to treat rheumatoid arthritis and their activity is attributed to copper ions.
Gold salts are also used as drugs to treat arthritis, together with known antiinflammatory products of a steroid and non-steroid type (US 4,746.504). Many silver salts, such as silver fluoride, silver iodide, silver lactate, have been used as antibacterial agents for topical use. Their antimicrobial activity is due to the action of the Ag+ ions. Heavy metal salts of hyaluronic acid are therefore already known to the state of the art, such as silver, gold, cerium and tungsten. The reaction between a sodium hyaluronate aqueous solution and a silver nitrate solution gives the silver salt of hyaluronic acid. Pharmaceutical preparations containing all these compounds are used to advantage for the treatment of burns, wounds and some ophthalmic infections such as gonococcus-induced conjunctivitis (A. Nimrod and B. Greenman, US Patent No. 4,746,504, May 24, 1988) .
However, neither hyaluronic acid nor hyaluronic acid partial or total ester derivatives wherein one or more hydroxy functions of its 1,4 β- D-glucuronic acid and 1,3-β-N-acetyl-D-glucosamine alternating repeating units esterified with a carboxyl group of succinic acid to form the succinic hemiester of hyaluronic acid or hyaluronic acid total or partial esters are known to the state of the art. SUMMARY OF THE INVENTION
The present invention concerns a succinic hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester and its inorganic salt with a heavy metal.
In particular the succinic acid hemiester with hyaluronic acid, or with a hyaluronic acid total or partial ester is characterized by having the following repeating unit (I):
(I) wherein Rj_ , R2 and R equal or different from each other are H or C0- (CH2)2-C00Y' wherein Y is a negative charge or H, R is OH, 0" or an alcoholic residue.
The hyaluronic acid esters contemplated for preparing the succinic acid hemiester are the total or partial ester with alcohol of the aliphatic or cycloaliphatic series, which do not themselves possess a notable pharmacological action disclosed in USP 4 ,851.521, which we incorporate herewith by reference. The heavy metal salt of the succinic acid hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester are in particular characterized by having the following repeating unit (II):
(ID wherein R R2 and R equal or different from each other are H or C0- (CH2)2-C00", R is 0", or an alcoholic residue, (Xz+) is a cation of a heavy metal in which z is a number comprised between 1 and 6, p is an integer or a decimal number, comprised between 0.1 and 5 provided that p(Xz+) is equal to the number of anionic groups COO" present in said repeating unit. The heavy metal salts according to the present invention are characterized by having a far greater negative charge density than the corresponding heavy metal salt of the starting hyaluronate . Indeed, the new substituting group, i.e. succinic acid. can bind, theoretically, to all the alcoholic functions of the repeating unit, giving a polysaccharide containing up to four succinic groups per repeating unit and therefore four more negative charges available for the formation of salts. A further subject of the present invention relates to the process for preparing said succinic acid hemiester with hyaluronic acid or with a hyaluronic acid partial ester and the corresponding heavy metal salt. This process in particular comprises the following steps: a) converting the hyaluronic acid sodium salt into a salt selected from the group consisting of pyridinium, tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium salt, in the presence of water and an aprotic solvent, b) treating the solution coming from step (a) with succinic anhydride in the presence of an organic base, as the catalyst, removing the pyridinium, tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, or tetraarylphosphonium cation by dialysis, thereby obtaining the succinic acid hemiester having the repeating unit (I) provided that at least one of said repeating units (I) has R = OH or 0", and optionally recovering the obtained product by freeze-drying, c) treating the solution directly coming from the preceding step or an aqueous solution of the recovered solid product coming from the preceding step with an aqueous solution of an inorganic salt of the heavy metal, and recovering the product by filtration and vacuum drying. In case of the preparation of the heavy metal salt with the succinate hemiester of the total ester of hyaluronic acid, the process according to the present invention contemplates the following steps: b') treating the hyaluronic acid ester dissolved or suspended in a mixture of water and an aprotic solvent with succinic anhydride in the presence of an organic base, as the catalyst, thereby obtaining the succinic acid hemiester having the repeating units (I) wherein R is a residue of an alcohol, and optionally recovering the obtained product by freeze-drying, c' ) treating the solution directly coming from the preceding step or an aqueous solution of the recovered solid product coming from the preceding step with an aqueous solution of an inorganic salt of the heavy metal, and recovering the product by filtration and vacuum drying. The heavy metal salts of succinic acid hemiester with a hyaluronic acid or with a partial or total hyaluronic acid ester according to the present invention can be used to advantage as antimicrobial, antibacterial and disinfectant agents, for the treatment of wounds, burns and ophthalmia, or they can be incorporated in suitable pharmaceutical forms, optionally in association with one or more other pharmacologically active substances, having a similar therapeutic activity.
In addition they can be advantageously used as disinfectant agents, not only for the preparation of drugs, but also as active ingredients for the preparation of the so-called health care products, such as cosmetic creams and ointments, shave and after shave lotions and hair lotions etc. or biomaterials such as membranes non-woven tissues. gauzes , etc.
The heavy metal salts of succinyl monoesters of hyaluronic acid can be also advantageously used as antiinflammatory agents in the treatment of arthritis and inflammations affecting the joints optionally in association with other pharmaceutically active principles having a similar therapeutical activity. DETAILED DESCRIPTION OF THE INVENTION
The term "heavy metal" encompasses any pharmaceutically active metal in the 4, 5 or 6 period of the periodic table. The preferred heavy metal salts according to the present invention are those whose cation is: zinc, silver, copper, gold, cerium and tungsten salts of succinic derivatives of hyaluronic acid. It has in fact been found that compared with the corresponding salts with hyaluronic acid or with hyaluronic acid partial esters these salts offer an advantage over the already-known products containing heavy metal salts, because the salts according to the present invention can bind a high number of heavy metal cations. Indeed, while hyaluronic acid can bind only one counter-ion per repeating unit, the salts according to the present invention bind at least twice as many counter-ions per repeating unit.
It is therefore advantageous to use these heavy metal salts with higher concentrations of metal for the therapeutic applications identified and described in the text, as this is the most active component in the preparation. Hyaluronic acid or hyaluronic acid esters of any molecular weight can be used to prepare succinyl derivatives thereof. In the present invention, samples of hyaluronic acid with a molecular weight of between 30,000 and 760,000 Daltons were used, but this range is not critical for the purpose of the present invention.
Preferred succinic acid hemiesters of hyaluronic acid or hyaluronic acid esters are those having in the repeating unit (I) R^ = R2 = R = H and the corresponding heavy metal salts wherein in the repeating unit (II) X is selected from the group consisting of: silver, gold, copper, zinc, z is comprised between 1 and 3 and p is comprised between 0.3 and 2.
Another class of preferred succinic acid hemiesters with hyaluronic acid or hyaluronic acid esters are those having at least one repeating unit (I) wherein R^ R, = H and R = CO-fC^^-COOY and at least one repeating unit (I), wherein R2 = R = H, and Ri =C0- (CH2)2_C00Y has the above mentioned meanings and the corresponding heavy metal salts have at least one repeating unit (II) wherein Rj= R-, = H and R2 = CO-fC^^-COO" and at least one repeating unit (II) wherein R2 = R = H, Rι= C0-(CH2)2-C00" , X is selected from the group consisting of: silver, gold, copper, zinc, z is comprised between 1 and 3 and p is comprised between 0.6 and 3-
In the process according to the present invention for preparing the succinic acid hemiesters with hyaluronic acid or with hyaluronic acid partial esters, in step (a) the hyaluronic acid is preferably converted to the corresponding pyridinium salt. In particular this conversion encompasses a previous dissolution of the hyaluronate sodium salt in a mixture of water and dimethylformamide, a treatment with a cationic exchange resin for obtaining the corresponding free hyaluronic acid. After removal of the resin the solution is neutralized with pyridine and the pyridinium salt is thus obtained. In step (b ) or (b 1 ) of both processes the amount of succinic anhydride is not critical , although it is preferable to add high excess with respect to hyaluronic acid. In fact the best results are obtained when the molar ratio of succinic anhydride /free OH groups present in the repeating unit ( III)
(III) wherein R has the above mentioned meanings, of the starting hyaluronic acid or hyaluronic acid partial ester, ranges between 1 and 90. Although the temperature is not critical, the best results are obtained if step (b) or (b' ) of both processes is carried out at 70βC . The preferred organic base used as catalyst in step (b ) or (b ' ) of both processes is selected from the group consisting of 4-dimethylaminopyridine , pyridine, or mixtures thereof . By using large amounts of 4-dimethylamminopyridine a succinic acid hemiester with hyaluronic acid or a hyaluronic acid ester with a high degree of succinylation is obtained, by using pyridine alone or in admixture with small quantities of 4-dimethylaminopyridine a succinic acid hemiester with hyaluronic acid with a low degree of succinylation is obtained. Anyway the stronger the reaction conditions, such as temperature, reaction times etc., the greater the degree of esterification of the derivatives formed.
For the preparation of the Ag salt of the succinate hemiester with hyaluronic acid or a hyaluronic acid ester, in step (c) or (c') the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of silver nitrate to form the silver salt of succinate hemiester with hyaluronic acid or hyaluronic acid ester. The Ag salt according to the present invention precipitates from the solution and is recovered by filtration or centrifugation. The precipitate is then washed with ethanol and vacuum dried at 4θ°C. The silver compounds of the succinyl derivatives are prepared in the complete dark. All the operations to prepare the silver nitrate solutions, and to prepare the succinyl silver hyaluronate were performed in the dark and the resulting products were stored away from sources of light.
For the preparation of the Cu salts of the succinate hemiester with hyaluronic acid or a hyaluronic acid ester, in step (c) or (c1) of both processes, the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of CuCl2 to form the Cu salt of succinate hemiester with hyaluronic acid or with the hyaluronic acid ester. For the preparation of the Zn salts of the succinate hemiester with hyaluronic acid or a hyaluronic acid ester, in step (c) or (c') of both processes the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of ZnCl2 to form the Zn salts of the succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.
For the preparation of the Au salts of the succinate hemiester with hyaluronic acid or a hyaluronic acid ester, in step (c) or (c1) of both processes the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of HAuCl^ to form the Au salts of the succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.
The pharmaceutical compositions according to the present invention to be used for the treatment of burns, wounds and ophthalmia preferably contain the Ag salt according to the present invention and are moreover in the form of ointments, creams gels.
The pharmaceutical compositions to be used for the treatment of osteoarticular diseases preferably contain Au, Zn, Cu salts or mixtures thereof. We report hereafter some specific examples for the preparation of 0- succinylhyaluronates and relative heavy metal salts, but any variation not specifically reported in the following examples is to be considered as coming within the scope of the present invention. Example for the preparation of succinic acid hemiester with hyaluronic acid having the repeating unit (I) Example 1:
A solution of sodium hyaluronate (HA-Na, 1 g, MW 160,000) in distilled water (35 ml) and N,N-dimethylformamide (DMF, 100 ml) was stirred for ten minutes in the presence of ion exchange resin (3 G, IR 120 H +), after which the resin was removed by filtration after further dilution with DMF (100 ml). The solution was then neutralized with an excess of pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py) . The viscous solution was then carefully evaporated in a vacuum to remove the water present, taking care not to allow the total volume of solution to drop below about 100 ml. This procedure was repeated three times, each time adding DMF (20 ml). The solution was then treated with succinic anhydride (3 g) and pyridine (10 ml) while being stirred at room temperature for 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml) , dialized against distilled water (3 times 750 ml) and freeze-dried to give hyaluronic acid succinylate (930 mg) . Table 1 shows the assignment of the chemical shift values of the ^C.n.m.r. (50.3 MHz) spectrum of sample 1.
TABLE 1
N.M.R. Analysis shows a degree of succinylation on carbon 6 of the N- acetylglucosamine (N-6) of 0.2 (mol of succinic acid/mol of repeating unit of the polymer) . Example 2: A solution of sodium hyaluronate (HA-Na, 1 g, MW 30,000) in distilled water (35 ml) and N,N-dimethylformamide (DMF, 100 ml) was stirred in the presence of ion exchange resin (3 g, IR 120 H+) for 10 minutes and then the resin was removed by filtration after further dilution with DMF (100 ml). The solution was then neutralized with an excess of pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py) . The viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 100 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml). The solution was then treated with succinic anhydride (3 g) and pyridine (10 ml) while being stirred at 70°C for 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml), dialized against distilled water (3 times 750 ml) and freeze-dried to give hyaluronic acid succinylate (900 mg) . Table 2 reports the assignment of the chemical shift values of the spectrum (50.3 MHz) of sample 2). - TABLE 2
N.M.R. analysis gives a degree of succinylation on carbon 6 of the Nacetylglucosamine (N-6) of about 0.45 (mol of succinic acid/mol of repeating unit. Example 3: A solution of sodium hyaluronate (HA-Na, 0.5 g. MW 160,000) in distilled water (35 ml) and N,N-dimethylformamide (DMF 100 ml) was stirred in the presence of ion exchange resin (3 G, IR 120 H+) for 10 minutes and then the resin was removed by filtration after further dilution with DMF (75 ml). The solution was then neutralized with an excess of pyridine (6 ml) to give the pyridine salt of hyaluronic acid (HA-Py) . the viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 50 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (10 ml). The solution was then treated with succinic anhydride (2 g) , 4-dimethylaminopyridine (10 mg) and pyridine (10 ml), while stirring at 70°C for 48 hours. Further quantities of succinic anhydride were added (1 g) and pyridine (2.5 ml) and the mixture was stirred for another 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml), dialized against distilled water (3 times 750 ml) for 3 days and freeze-dried to give hyaluronic acid succinylate (450 mg) . The product was characterized by a high degree of viscosity when dissolved in water, the n.m.r. spectrum in particular was characterized by wide peaks due to the sample's high degree of viscosity. The degree of modification was assessed by potentiometric assay, and proved to be 1.8 (mol of succinic acid/mol of repeating unit) . Example 4 :
A solution of sodium hyaluronate (HA-NA, 0.5 g, MW 240,000) in distilled water (60 ml) and N.N-dimethylformamide (DMF 60 ml) was stirred in the presence of ion exchange resin (1 G, IR 120 H+) for 10 minutes, after which the resin was removed by filtration after further dilution with DMF (50 ml) . the solution was then neutralized with an excess of pyridine (6 L) to give the pyridine salt of hyaluronic acid (HA-Py) . The viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 100 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml). The gelatin like solution was then treated with succinic anhydride (2 g) and pyridine (5 ml) at 70βC, while being stirred for 18 hours. Further quantities of succinic anhydride (2.5 g) and 4- dimethylaminopyridine (200 mg) were added and the mixture was stirred for another 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml) and freeze-dried to give hyaluronic acid succinylate (450 mg) . The product is characterized by being highly viscous when dissolved in water, the n.m.r. spectrum in particular is characterized by very wide peaks due to the highly viscous character of the samples. The degree of modification was assessed by potentiometric assay and the result was 2.5 (mol of succinic acid/mol of repeating unit). Example 5: A solution of sodium hyaluronate (HA-Na, 1 g, MW 40,000) in distilled water (60 ml) and N,N-dimethylformamide (DMF 60 ml) was stirred in the presence of ion exchange resin (1 g, IR 120 H+) for 10 minutes, after which the resin was removed by filtration after further dilution with DMF (50 ml). The solution was then neutralized with an excess of pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py) . The viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below 0 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml). The solution was then treated with succinic anhydride (3 g) and pyridine (10 ml) at 70°C while stirring for 18 hours. Further quantities of succinic anhydride (2.5 g) and 4dimethylaminopyridine (200 mg) were added and the mixture was stirred for another 24 hours. The reaction mixture, which was brown in colour, was then concentrated, gathered with distilled water (20 ml) , dialized against distilled water (3 times 750 ml) and freeze-dried to give hyaluronic acid succinylate (850 mg) . The degree of succinylation was assessed by potentiometric assay and was 3-5 (mol of succinic acid/mol of repeating unit). Example 6:
A solution of sodium hyaluronate (HA-Na, 0.5 g. MW 760,000) in distilled water (60 ml) and N,N-dimethylformamide (DMG 60 ml) was stirred in the presence of ion exchange resin (1 g, IR 120 H+) for 10 minutes, after which the resin was removed by filtration after further dilution with DMF (50 ml). The solution was then neutralized with an excess of pyridine (6 ml) to give the pyridine salt of hyaluronic acid (HA-Py) . The viscous solution was then carefully evaporated to remove the water present, without allowing the total volume of solution to drop below about 50 ml. This procedure was repeated three times, each time with the addition of DMF (20 ml). The gelatin-like solution was then treated with succinic anhydride (2 g) and 4-dimethylaminopyridine (200 mg) and the mixture was stirred for another 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml), dialized against distilled water (3 times 750 ml) and freeze- dried to give hyaluronic acid succinylate (430 mg) . The product is characterized by being highly viscous when dissolved in water, the n.m.r. spectrum in particular is characterized by very wide peaks due to the highly viscous character of the samples. The degree of modification was assessed by potentiometric assay and was 2.5 (mol of succinic acid/mol of repeating unit) .
Examples of the preparation of silver salts of 0-succinyl hyaluronate Example :
100 mg of 0-succinyl hyaluronate, prepared as described in Example 1 were dissolved in 10 ml of distilled water. The polymer solution was then supplemented with 10 ml of a solution of AgNOo IN. The white precipitate thus formed was kept in suspension while being stirred constantly for two hours, and was then gathered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven set at 4θ°C. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed a silver content of 23-5$ in weight, equal to 87$ of the theoretical stoichiometric value. Example 8: 70 mg of hyaluronic acid succinylate, prepared as described in Example 3 were dissolved in 14 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 14 ml of a solution of AgNO IN. A grey precipitate formed immediately and was kept in suspension while being constantly stirred for two hours, after which it was gathered by filtration through a Buchner funnel. It was washed several times with ethanol and dried in a vacuum oven set at 4θβC. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 21% in weight, equal to 11% of the theoretical stoichiometric value. Example 9: 100 mg of hyaluronic acid succinylate, prepared as described in Example 4, were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of AgNO 2N. A white precipitate formed immediately and was kept in suspension while being constantly stirred for two hours. It was then recovered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven set at 4θβC. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 28.8% in weight, equal to 70.5% of the theoretical stoichiometric value. Example 10:
100 mg of hyaluronic acid succinylate, prepared as described in Example 5. were dissolved in 10 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 10 ml of a solution of AgNO IN. A brownish precipitate formed immediately and was kept in suspension while being constantly stirred for two hours, after which it was recovered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven at 4θ°C. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 31$. equal to 10.2% of the theoretical stoichiometric value. Example 11: 100 mg of hyaluronic acid succinylate, prepared as described in Example 6, were dissolved in 10 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 10 ml of a solution of AgNO IN. A brownish precipitate was immediately formed, which was kept in suspension while being constantly stirred for two hours, after which it was recovered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven set at 40CC. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 21% in weight, equal to 11% of the theoretical stoichiometric value.
Examples of the preparation of zinc salts of hyaluronic acid succinylate
Example 12:
100 mg of hyaluronic acid succinylate, prepared as described in Example 1 were dissolved in 10 ml of distilled water. The polymer solution was then supplemented with 10 ml of a solution of ZnCl2 0.2 N. The solution was stirred constantly for 2 hours, after which 3 volumes of ethanol were added to precipitate the soluble zinc salt. The precipitate was recovered by centrifugation at 3.000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 4θ°C. Atomic absorption analysis showed a zinc content of 10 , equal to 101% of the theoretical stoichiometric value. Example 13 :
100 mg of hyaluronic acid succinylate prepared as described in Example
3 were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of ZnCl2 2 N. After the addition of zinc salt, a powdery precipitate was formed, which was recovered by centrifugation at 3.000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 4θβC. Atomic absorption analysis showed the zinc content in the sample to be 15-3%. equal to 105% of the theoretical stoichiometric value.
Example 14:
100 mg of hyaluronic acid succinylate prepared as described in Example
4 were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of ZnCl2 2N. After the addition of zinc salt, a powdery precipitate was formed which was recovered by centrifugation at 3.000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 4θ°C. Atomic absorption analysis showed the zinc content of the sample to be 11 .1% i weight, equal to 105% of the theoretical stoichiometric value.
Example of the preparation of the copper salt of hyaluronic acid succinylate
Example 15:
100 mg of hyaluronic acid succinylate prepared as described in Example 5 were dissolved in 10 ml of distilled water. The polymer solution was then supplemented with 10 ml of a solution of CuCl2 2N. After the addition of copper salt a blue precipitate was formed which was recovered by centrifugation at 3.000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 4θβC. Atomic absorption analysis showed the copper content of the sample to be 21.4% in weight, equal to 110% of the theoretical stoichiometric value. It is therefore probable that a small amount of copper salt is incorporated by the polymer during precipitation of the derivative. Example of the preparation of gold salt of hyaluronic acid succinylate Example 16: 100 mg of hyaluronic acid succinylate prepared as described in Example 3 were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was then supplemented with 20 ml of a solution of HAuCLij 0.5N. After addition of gold salt, a precipitate was formed which was recovered by centrifugation at 3.000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven at 4θcC. The gold content in the sample proved to be 13% in weight, equal to 44% of the theoretical stoichiometric value.

Claims

1. Succinic acid hemiester with hyaluronic acid, or with a hyaluronic acid partial or total ester having the following repeating unit (I):
wherein R1, R2 and R3 equal or different from each other are H or CO-(CH2)2-COOY. wherein Y is a negative charge or H, R is OH, O- or an alcoholic residue.
2. The succinic acid hemiester according to claim 1 wherein in the repeating unit (I) R1 = R2 = R3 = H.
3. The succinic acid hemiester according to claim 1 having at least one repeating unit (I) wherein R1= R3 = H and R2 = CO-(CH2)2-COOY and at least one repeating unit (I), wherein R2 = R3 = H, and R1 =CO- (CH2)2-COOY.
4. Heavy metal salt of succinic acid hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester, having the following repeating unit (II)
)
wherein R1, R2 and R3 equal or different from each other are H or CO- (CH2)2-COO-, R is O-, or an alcoholic residue, (Xz+) is a cation of a heavy metal in which z is a number comprised between 1 and 6, p is an integer or a decimal number, comprised between 0.1 and 5 provided that p(Xz+) is equal to the number of anionic groups COO- present in said repeating unit.
5- The heavy metal salt according to claim 4 wherein X is selected from the group consisting of Ag, Cu, Zn, Au, Ce, W.
6. The heavy metal salt according to one of claims 4 and 5 wherein R1 = R2= R3 = H, X is selected from the group consisting of: silver, gold, copper, zinc, z is comprised between 1 and 3 and p is comprised between 0.3 and 2.
7. The heavy metal salt according to one of claims 4,5 and 6, having at least one repeating unit (II) wherein R1= R3 = H and R2 = CO- (CH2)2-COO- and at least one repeating unit (II) wherein R2 = R3= H, R1= CO-(CH2)2-COO-, X is selected from the group consisting of: silver, gold, copper, zinc, z is comprised between 1 and 3 and p is comprised between 0.6 and 3.
8. A process for preparing the heavy metal salt of succinic acid hemiester with hyaluronic acid or with a partial ester of hyaluronic acid according to one of claims 4, 5. 6 and 7 comprising the following steps:
a) converting the hyaluronic acid sodium salt into a salt selected from the group consisting of pyridinium, tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium salt, in the presence of water and an aprotic solvent,
b) treating the solution coming from step (a) with succinic anhydride in the presence of an organic base, as the catalyst, removing the pyridinium tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, or tetraarylphosphonium cation by dialysis thereby obtaining the succinic acid hemiester with hyaluronic acid or a partial ester thereof having at least one repeatint unit (I)
wherein R1, R2 and R3 equal or different from each other are H or CO-(CH2)2-COOY, wherein Y is a negative charge or H, R is OH, O- or an alcoholic residue, provided that at least in one repeating unit (I) R is OH or O- and optionally recovering the obtained product by freeze-drying, c) treating the solution directly coming from the preceding step or an aqueous solution of the recovered solid product coming from the preceding step with an aqueous solution of an inorganic salt of the heavy metal, and recovering the product by filtration and vacuum drying.
9. The process according to claim 8 wherein in step (a) the hyaluronic acid is converted to the corresponding pyridinium salt by using the following operating conditions:
i) dissolving of the hyaluronate sodium salt in a mixture of water and dimethylformamide,
ii) a treatment with a cationic exchange resin to obtain the corresponding free hyaluronic acid.
iii) neutralizing the reaction mixture with pyridine thereby obtaining the pyridinium salt.
10. A process for preparing the heavy metal salts of succinic acid hemiesters with a hyaluronic acid total ester comprising the following steps:
b') treating the hyaluronic acid ester dissolved or suspended in a mixture of water and an aprotic solvent with succinic anhydride in the presence of an organic base, thereby obtaining the succinic acid hemiester having the repeating unit (I)
wherein R is a residue of an alcohol, and optionally recovering the obtained product by freeze-drying,
c') treating the solution directly coming from the preceding step or an aqueous solution of the recovered solid product coming from the preceding step with an aqueous solution of an inorganic salts of the heavy metal, and recovering the product by filtration and vacuum drying.
11. The process according to one of claims 8 and 9 or the process according to claim 10 wherein step (b) or (b') is carried out by using a molar ratio of succinic anhydride /free OH groups present in the following repeating unit (III),
of the starting hyaluronic acid or hyaluronic acid partial or total ester, which ranges between 15 and 90 and at 70ºC and the catalyst is selected from the group consisting of 4- dimethylaminopyridine , pyridine, or mixtures thereof.
12. The process according to one of claims 8, 9 or 11 or the process according to one of claims and 10 and 11 for preparing the Ag salts of the succinic acic hemiester with hyaluronic acid or a hyaluronic acid ester wherein in step (c) or (c') the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with a hyaluronic acid total or partial ester is treated with an aqueous solution of silver nitrate.
13. The process according to one of claims 8, 9 or 11 or the process according to one of claims 10 and 11 for preparing the Zn salts of the succinic acid hemiester with hyaluronic acid or with a hyaluronic acid ester wherein in step (c) or (c') the succinic acid hemiester with hyaluronic acid or with hyaluronic acid total or partial ester is treated with an aqueous solution of ZnCl2.
14. The process according to one of claims 8, 9 and 11 or the process according to one of claims 10 and 11 for preparing the Cu salts of the succinic acic hemiester with hyaluronic acid or a hyaluronic acid ester wherein in step (c) or (c') .the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is treated with an aqueous solution of CuCl2.
15. The process according to one of claims 8, 9 and 11 or the process according to one of claims 10 and 11 for preparing the Au salts of the succinic acid hemiester with hyaluronic acid or a hyaluronic acid ester wherein in step (c) or (c') the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is treated with an aqueous solution of HAuCl4.
16. A therapeutic composition containing as the active ingredient at least one heavy metal salt of succinic acid hemiester with hyaluronic acid or a hyaluronic acid total or partial ester according to one of claims 4, 5, 6, or 7 optionally in association with other active ingredients having a similar therapeutical activity.
17. The therapeutic composition according to claim 16 for the treatment of burns, wounds and ophthalmia.
18. The therapeutic compositions according to one of claims 16 or 17 in the form of ointments, creams gels.
19. The therapeutic compositions according to one of claims 16, 17 or 18 containing as the active ingredients an Ag salt of a succinic acid hemiester with hyaluronic acid or a hyaluronic acid total or partial ester.
20. The therapeutic compositions according to claim 16 for the treatment of osteoarticular diseases.
21. The therapeutic compositions according to one of claims 16 and 20, containing as the active ingredient at least one heavy metal salt of succinic acid hemiester with hyaluronic acid or with a hyaluronic acid ester selected from the group consisting of salts of Au, Cu, and Zn, or mixtures thereof.
22. A health care composition containing at least one heavy metal salt of succinic acid hemiester with hyaluronic acid or a hyaluronic acid ester according to one of claims 4, 5. 6 or 7.
23. Biomaterial containing at least one heavy metal salt according to one of claims 4, 5. 6 or 7.
EP96916030A 1995-05-10 1996-05-08 Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions Expired - Lifetime EP0827514B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITPD950090 1995-05-10
IT95PD000090A IT1281877B1 (en) 1995-05-10 1995-05-10 Heavy metal salts of succinyl derivatives of hyaluronic acid and their use as potential therapeutic agents
PCT/EP1996/001979 WO1996035720A1 (en) 1995-05-10 1996-05-08 Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions

Publications (2)

Publication Number Publication Date
EP0827514A1 true EP0827514A1 (en) 1998-03-11
EP0827514B1 EP0827514B1 (en) 1999-08-11

Family

ID=11391041

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96916030A Expired - Lifetime EP0827514B1 (en) 1995-05-10 1996-05-08 Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions

Country Status (9)

Country Link
EP (1) EP0827514B1 (en)
JP (1) JP4264671B2 (en)
AT (1) ATE183206T1 (en)
AU (1) AU695512B2 (en)
CA (1) CA2220682C (en)
DE (1) DE69603721T2 (en)
ES (1) ES2137694T3 (en)
IT (1) IT1281877B1 (en)
WO (1) WO1996035720A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0781566B1 (en) * 1995-12-26 2004-07-28 Toyo Boseki Kabushiki Kaisha Organic solvent-soluble mucopolysaccharide, antibacterial antithrombogenic composition and medical material
IT1291452B1 (en) 1997-04-14 1999-01-11 Fidia Advanced Biopolymers Srl COATING BASED ON HYALURONIC ACID AND ITS DERIVATIVES FOR THE PROTECTION OF ELECTRONIC PARTS FROM EXTERNAL AGENTS
IT1294797B1 (en) * 1997-07-28 1999-04-15 Fidia Advanced Biopolymers Srl USE OF HYALURONIC ACID DERIVATIVES IN THE PREPARATION OF BIOMATERIALS WITH PHYSICAL AND BUFFERING HEMOSTATIC ACTIVITIES
US6872819B1 (en) * 1998-05-27 2005-03-29 Fidia Advanced Biopolymers S.R.L. Biomaterials containing hyaluronic acid derivatives in the form of three-dimensional structures free from cellular components or products thereof for the in vivo regeneration of tissue cells
ITPD980149A1 (en) * 1998-06-17 1999-12-17 Fidia Advanced Biopolymers Srl THREE-DIMENSIONAL PROSTHESES INCLUDING HYALURONIC ACID DERIVATIVES TO REPAIR OR REBUILD DAMAGED TISSUES AND PROCESS FOR THE
JP2003089647A (en) * 1999-03-10 2003-03-28 Takada Seiyaku Kk Articular disease therapeutic agent
EP1198253A2 (en) 1999-06-18 2002-04-24 ML Laboratories Plc Biologically active materials
WO2004024197A1 (en) 2002-09-11 2004-03-25 Johnson & Johnson Medical Limited Wound dressing materials comprising complexes of anionic polysaccharides with silver
GB2392913B (en) * 2002-09-11 2007-04-04 Johnson & Johnson Medical Ltd Wound dressings comprising complexes of oxidised celluloses with silver
DK200301128A (en) * 2003-08-05 2005-02-06 Thomsen Joern Oddershede Grant Preparation
US7993678B2 (en) * 2005-09-26 2011-08-09 Novozymes Biopolymer A/S Hyaluronic acid derivatives
IT1402786B1 (en) * 2010-11-19 2013-09-18 Fidia Farmaceutici PHARMACEUTICAL COMPOSITIONS WITH ANTIBACTERIAL AND CICATRIZING ACTIVITIES
CZ2012842A3 (en) 2012-11-27 2014-08-20 Contipro Biotech S.R.O. C6-C18-acylated hyaluronate-based nanomicellar composition, process for preparing C6-C18-acylated hyaluronate, process for preparing nanomicellar composition and stabilized nanomicellar composition as well as use thereof
EP3226905B1 (en) 2014-02-27 2021-12-22 Synartro AB Hyaluronan conjugates with pharmaceutically active substances, methods and compositions
CZ2014451A3 (en) 2014-06-30 2016-01-13 Contipro Pharma A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, process of its preparation and use
CZ309295B6 (en) 2015-03-09 2022-08-10 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of its preparation and use
MA41912A (en) * 2015-04-07 2018-02-13 Hyalblue S R L GLYCOSAMINOGLYCANE ESTERS, PROCESSES FOR THEIR PREPARATION AND USE IN FORMULATIONS FOR OPHTHALMIC USE
CZ306479B6 (en) 2015-06-15 2017-02-08 Contipro A.S. A method of crosslinking polysaccharides by using photolabile protecting groups
CZ306662B6 (en) 2015-06-26 2017-04-26 Contipro A.S. Sulphated polysaccharides derivatives, the method of their preparation, the method of their modification and the use
CZ308106B6 (en) 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, preparing and using them
WO2019121488A1 (en) * 2017-12-21 2019-06-27 Nicox S.A. Nitric oxide releasing hyaluronic esters
JP7066909B1 (en) * 2020-12-25 2022-05-13 参天製薬株式会社 Aqueous eye drops containing high molecular weight compounds, silver salts and ionic isotonic agents
IT202100012737A1 (en) 2021-05-18 2022-11-18 Jointherapeutics S R L BLENDS OF POLYSACCHARIDES AND POLYAMINOSACCHARIDES WITH IMPROVED RHEOLOGICAL PROPERTIES
IT202100013787A1 (en) 2021-05-27 2022-11-27 Farmigea Spa A COMPOSITION FOR USE IN THE TREATMENT OF OCULAR AFFECTIONS, SUCH AS DRY EYE DISEASE, ESPECIALLY AFTER EYE SURGERY
IT202200004613A1 (en) 2022-03-10 2023-09-10 Cmed Aesthetics S R L “PROCESS FOR PREPARATION OF STERILE PRODUCTS”
WO2024038087A1 (en) 2022-08-16 2024-02-22 Synartro Ab Method for preparing sterile compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5436388A (en) * 1977-08-26 1979-03-17 Sumitomo Electric Ind Ltd Porous polysaccharide and its preparation
EP0066283B1 (en) * 1981-06-02 1986-09-10 Eupan Corporation Eustatic composition for nonspecifically facilitating and amplifying the generalized homeostatic regulation and maintenance, compensation and repair in living organisms
CA1291034C (en) * 1987-10-19 1991-10-22 Mostafa S. Fahim Composition for promoting epithelial regeneration
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US4746504A (en) * 1986-03-14 1988-05-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9635720A1 *

Also Published As

Publication number Publication date
ITPD950090A0 (en) 1995-05-10
AU5894496A (en) 1996-11-29
CA2220682A1 (en) 1996-11-14
WO1996035720A1 (en) 1996-11-14
AU695512B2 (en) 1998-08-13
EP0827514B1 (en) 1999-08-11
ES2137694T3 (en) 1999-12-16
JPH11504668A (en) 1999-04-27
CA2220682C (en) 2006-10-24
DE69603721T2 (en) 2000-01-13
ATE183206T1 (en) 1999-08-15
JP4264671B2 (en) 2009-05-20
DE69603721D1 (en) 1999-09-16
ITPD950090A1 (en) 1996-11-10
IT1281877B1 (en) 1998-03-03

Similar Documents

Publication Publication Date Title
EP0827514B1 (en) Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions
DE69610370T3 (en) Antioxidant-grafted polysaccharides and their uses
KR870001901B1 (en) Preparation method of hialuronic ester and its salts
DE60104703T2 (en) NEW NETWORKED DERIVATIVES OF HYALURONIC ACID.
DE69903351T3 (en) NETWORKED HYALURONIC ACID AND ITS MEDICAL USES
JP5797673B2 (en) Chemically modified polyaminosaccharide with hydrocarbyl sultone compound (A HYDROCARBYL SULTONE COMPOUND)
US5554598A (en) Method of treating crural or decubitus ulcer with zinc hyaluroric acid complex
DK1117695T3 (en) Biocompatible polymers, THE COMPOUNDS CONTAINING THEM AND THEIR USE FOR THE PREPARATION OF MEDICINES
DE69722434T2 (en) BUTTERIC ACID ESTER WITH ANTIPROLIFERATIVE EFFECT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2001522385A (en) N-sulfated hyaluronic acid compound, derivative thereof and production method
HU204858B (en) Process for producing bridge bonded esters of hyaluronic acid
JP2001510713A (en) Use of a hyaluronic acid derivative in the manufacture of a biocompatible material having physical hemostatic and embolic activity and prophylactic activity against adhesion formation after anastomosis
JP6000511B2 (en) Butyric acid-formic acid mixed esters of acidic polysaccharides and their preparation and use as skin cosmetics
DE60113398T2 (en) POLYSACCHARIDESTER OF N-DERIVATIVES OF GLUTAMIC ACID
US6017901A (en) Heavy metal salts of succinic acid hemiesters with hyaluronic acid or hyaluronic acid esters, a process for their preparation and relative pharmaceutical compositions
EP0410002B1 (en) Anti-hiv drug
EP2814848B1 (en) Partially depolymerized glycosaminoglycan silver and gold salts
EP4063399A1 (en) Thiol-modified polymer compound, and preparation method therefor and application thereof
EP3052529A1 (en) Single-step functionalization and cross-linking of hyaluronic acid
WO2019211483A1 (en) A composition for reduction of scar formation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980409

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19990811

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990811

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990811

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990811

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19990811

REF Corresponds to:

Ref document number: 183206

Country of ref document: AT

Date of ref document: 19990815

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: N&G PATENT SERVICES S.A.

REF Corresponds to:

Ref document number: 69603721

Country of ref document: DE

Date of ref document: 19990916

ET Fr: translation filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

ITF It: translation for a ep patent filed

Owner name: NOTARBARTOLO & GERVASI S.P.A.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991111

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991111

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2137694

Country of ref document: ES

Kind code of ref document: T3

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000508

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20001130

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: FIDIA FARMACEUTICI S.P.A.

Free format text: FIDIA ADVANCED BIOPOLYMERS S.R.L.#VIA DE'CARPENTIERI, 3#72100 BRINDISI (IT) -TRANSFER TO- FIDIA FARMACEUTICI S.P.A.#VIA PONTE DELLA FABBRICA, 3/B#35031 ABANO TERME (PD) (IT)

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CA

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050508

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20100419

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100419

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100416

Year of fee payment: 15

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20110616

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 183206

Country of ref document: AT

Kind code of ref document: T

Effective date: 20110508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110508

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110509

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150527

Year of fee payment: 20

Ref country code: ES

Payment date: 20150526

Year of fee payment: 20

Ref country code: DE

Payment date: 20150528

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20150527

Year of fee payment: 20

Ref country code: FR

Payment date: 20150519

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69603721

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20160507

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160507

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20160509